David Segal nomination, page-97

Im not too sure about why all the attention to the board . Despite been recently demolished by Southoz with good reason they do have their strengths besides we've all screwed up in our careers on occasion. Imo the problem appears to lie at senior management. Putting the unforthcoming publishing aside why is it that our CSO and senior scientists never present the coys technology to industry . Iv been to more pain and related conferences around the world than these guys albeit as the handbag . Its rather obvious to me that many commercial relationships germinate at this level . Lots bio and pharma interaction . CSO's and senior scientists mixing it . Its almost as if POH are reluctant and commercialy anti social . Why ?
Iv developed some good friends and associates in pharma but mention poh and after some research the coy is seen as a ghost. Sweet all in the scientific literature and AWOL everywhere else .
How can a board perform when it appears that the rest of management cant ? Perhaps your scrutiny needs to be redirected.